Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT06206369
Recruiting Observational

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression

NCT06206369 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Amsterdam UMC, location VUmc
Phase
Observational
Started
2023-10-31
Last updated
2024-01-16

Condition(s) studied

Aneurysm AbdominalPeripheral Arterial Disease

Investigational drug(s) / intervention(s)

No intervention, retrospective study

No intervention, retrospective study: No intervention, retrospective study

Study summary

The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). The study plans to gather and analyze data from at least 5000 AAA and 6000 PAD patients, combining existing cohorts and retrospectively collected data. During this project, AI tools will be developed to perform automatic anatomical segmentation and analyses on multimodal imaging. AI prediction algorithms will be developed based on multisource data (imaging, medical history, -omics).

Eligibility

Sex
ALL
Min age
40 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Males and females, 40-90 years old, with an AAA \>3cm. This includes patients with infrarenal, juxtarenal, suprarenal, iliac (defined as 1.5x its normal diameter) aneurysms, as well as mycotic aneurysms. Patients that have had interventions or ruptures will also be included * Males and females, 40-90 years old, all PAD patients (Fontaine stages 1,2,3, and 4). Exclusion Criteria: * Patients with an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Hospital District of Helsinki and Uusimaa (HUS) Helsinki Finland Recruiting
Asklepios kliniken hamburg Hamburg Germany Recruiting
Amsterdam UMC Amsterdam Netherlands Recruiting
University Hospital Center of São João Porto Portugal Recruiting
University Clinical Centre of Serbia Belgrade Serbia Recruiting
Oxford University Hospitals Oxford United Kingdom Recruiting

More Amsterdam UMC, location VUmc trials in the Netherlands

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS Recruiting
Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis Starting soon
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes Recruiting
COLLISION RELAPSE Trial Recruiting
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma Recruiting

Other trials for the same condition

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Recruiting
Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage Recruiting
A Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy Active, not recruiting
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease Recruiting
SELUTION4BTK Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06206369 on ClinicalTrials.gov ↗ ← All trials in the Netherlands